Haleos Labs Limited (HALEOSLABS) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Trident Lifeline

Medico Remedies

Everest Organics

Haleos Labs Limi

Jenburkt Pharma

Albert David

Nectar Lifesci.

Kerala Ayurveda

Solara Active PP

Amanta Healthcar

Infinium Pharma

Why is Haleos Labs Limited ?

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 9.15%

Poor long term growth as Net Sales has grown by an annual rate of 10.05% and Operating profit at 18.86% over the last 5 years

The company has declared positive results in Sep'2025 after 2 consecutive negative quarters

PBT LESS OI(Q) At Rs 8.07 cr has Grown at 203.38%
DEBT-EQUITY RATIO(HY) Lowest at 0.34 times
OPERATING PROFIT TO INTEREST(Q) Highest at 8.38 times

With ROCE of 11, it has a Attractive valuation with a 1.8 Enterprise value to Capital Employed

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 17.81%, its profits have fallen by -14.5%

Majority shareholders : Promoters

Market Beating performance in long term as well as near term

Along with generating 17.81% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Haleos Labs Limi should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Haleos Labs Limi for you?

High Risk, Medium Return

Absolute

Risk Adjusted

Volatility

Haleos Labs Limi

13.97%

0.26

52.90%

Sensex

4.67%

0.39

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

10.05%

EBIT Growth (5y)

18.86%

EBIT to Interest (avg)

3.25

Debt to EBITDA (avg)

2.65

Net Debt to Equity (avg)

0.33

Sales to Capital Employed (avg)

1.28

Tax Ratio

27.39%

Dividend Payout Ratio

3.96%

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

9.07%

ROE (avg)

8.63%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.01

EV to EBIT

16.02

EV to EBITDA

10.64

EV to Capital Employed

1.76

EV to Sales

1.43

PEG Ratio

Dividend Yield

0.11%

ROCE (Latest)

11.00%

ROE (Latest)

9.06%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

13What is working for the Company

PBT LESS OI(Q)

At Rs 8.07 cr has Grown at 203.38%

DEBT-EQUITY RATIO(HY)

Lowest at 0.34 times

OPERATING PROFIT TO INTEREST(Q)

Highest at 8.38 times

PBDIT(Q)

Highest at Rs 13.58 cr.

OPERATING PROFIT TO NET SALES(Q)

Highest at 16.69%

PAT(Q)

At Rs 6.10 cr has Grown at 30.6%

EPS(Q)

Highest at Rs 20.20

-2What is not working for the Company

PAT(9M)

At Rs 13.23 cr has Grown at -24.70%

Loading Valuation Snapshot...

Here's what is working for Haleos Labs Limi

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 8.07 cr has Grown at 203.38%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Operating Profit to Interest - Quarterly

Highest at 8.38 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly

Lowest at 0.34 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit (PBDIT) - Quarterly

Highest at Rs 13.58 cr.

in the last five quarters

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly

Highest at 16.69%

in the last five quarters

MOJO Watch

Company's efficiency has improved

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 8.07 cr.

in the last five quarters

MOJO Watch

Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly

Highest at Rs 6.10 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 6.10 cr has Grown at 30.6%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 20.20

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)